Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose arsenic trioxide as a chemotherapy protector in patients with malignancies
NCT01428128Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2011
- Primary completion
- Jan 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in chemotherapy-induced toxicity, sponsored by UT Health San Antonio. Started Apr 2011; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chemotherapy-induced toxicity
Beyond the preview
Go deeper on NCT01428128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01428128.